Bronnen:
- Ciurea SO, Shah MV, Sakiba RM, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2017; Sep 14. pii: S1083-8791(17)30713-9. doi: 10.1016/j.bbmt.2017.09.005. [Epub ahead of print] ,Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975-81.,Passweg JR, Bartolomeo H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811-7.,Rashidi A, Ebadi M, Colditz DA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in older patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016;22:651-7.,Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoSOne. 2014;9:e109799.,Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2061-8.,Mori Y, Ikeda K, Inomata T, et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant. 2016;51:1584-7.,Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease failure of prior therapy. Blood. 2017;130:2243-50.,Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129-9.,Pusic I, Choi J, Fiola MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21:1761-9.